• Home
  • About Modra
    • Overview
    • Management Team
    • Supervisory Board
  • Technology
    • Oral Taxane Therapy
    • Patient Benefit
    • Publications
  • Pipeline
    • Overview
    • ModraDoc006/r
    • ModraPac005/r
    • Partnerships
  • Careers
  • News
    • News & Events
    • Press Releases
  • Contact
Dizy-Logo

  • Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

    27 May, 2022

  • Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer

    23 May, 2022

  • Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

    17 February, 2022

Follow Us

Press Releases

Press Releases

All Press Releases

  • May 27, 2022
  • Press Release

Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

Read More
  • May 23, 2022
  • Press Release

Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer

Read More
  • February 17, 2022
  • Press Release

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

Read More
  • April 27, 2021
  • Press Release

Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

Read More
  • February 12, 2021
  • Press Release

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

Read More
  • February 11, 2021
  • Press Release

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

Read More
  • August 14, 2019
  • Press Release

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

Read More
Contact
Modra Pharmaceuticals B.V.
Barbara Strozzilaan 201
1083 HN Amsterdam
The Netherlands
Phone: +31 (0)20-205 0188
E-mail: info@modrapharmaceuticals.com
Info
  • Privacy Policy